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Induction of the adaptive immune system is evaluated mostly by assessment of serum
antibody titers and T lymphocyte responses in peripheral blood, although T and B cell acti-
vation occurs in lymphoid tissues. In recent years, the release of microRNAs (miRNAs)
in the extra-cellular environment has been exploited to assess cell functions at distance
via measurement of serum miRNAs. Activated lymphocytes release a large amount of
nano-sized vesicles (exosomes), containing miRNA, however there are insufficient data to
determine whether this phenomenon is reflected in modulation of serum miRNAs. Inter-
estingly, miRNA signatures of CD4+ T cell-derived exosomes are substantially different
from intracellular miRNA signatures of the same cells. We have recently identified serum
circulating miR-150 as a sensor of general lymphocyte activation and we strongly believe
that miRNAs differentially released by specific CD4+ effectorT cell subsets (Th1,Th2,Th17,
and Treg) may serve as serum biomarkers of their elicitation in lymphoid tissues but also
in damaged tissues, potentially providing clinically relevant information about the nature of
immune responses in health and disease.
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BLOOD-CIRCULATING miRNAs AS BIOMARKERS IN HEALTH
AND DISEASE
MicroRNAs (miRNAs) are small single-stranded RNA molecules
(18–25 nt), that once loaded into the Argonaute protein of the
silencing complex, pair with messenger RNAs, directly effecting
post-transcriptional regulation (1). In recent years, it has been
found that most cells release miRNAs in the extra-cellular environ-
ment, predominantly in association with either vesicles or protein
complexes that protect them from RNAses (2–4). This release can
be a passive phenomenon that results from tissue damage, or an
active process as in the case of miRNAs actively secreted into the
surrounding environment by healthy cells, where once outside,
miRNAs can reach the bloodstream and constitute what it is now
referred to as the “blood-circulating extra-cellular miRNome.”
Extra-cellular miRNAs can be extracted from serum, plasma, and
other body fluids and profiled through microarray, real time quan-
titative PCR or sequencing. This possibility has been exploited
to assess cell functions at distance via measurement of serum
miRNAs and nowadays blood-circulating miRNAs are regarded
among the most promising clinical biomarkers for the diagno-
sis, prognosis, and therapeutic options of a variety of pathological
conditions such as cancer (5–7), cardiovascular diseases (8, 9), dia-
betes (10), liver pathologies (11, 12), and sepsis (13, 14), among
others [reviewed in Ref. (15)].
Circulating miRNAs as clinical biomarkers are not without
some technical challenges. First, dilution effects in blood limit the
amount of RNA per volume of starting material. Second, cellular
detritus, hemolysis, and the presence of contaminating compo-
nents constitute pre-analytical challenges, potentially impacting
reproducibility and sensitivity. Finally, as miRNAs are released by
virtually all cells in the body and most of the blood miRNAs are
released by large organs as well as highly dividing cells, specificity
is impacted by high background. However, the fact that serum
miRNAs circulate in different compartments might provide an
advantage. miRNAs circulate in association with vesicles of nano-
metric size (20–100 nm) called exosomes, that are formed by the
inward budding and subsequent fusion to the plasma membrane
of multivesicular endosomes (16); vesicles of larger size (0.2–
1µm) that bud directly from the plasma membrane, are called
microvesicles and comprise also apoptotic and senescent bod-
ies (17); in association with Argonaute protein in a vesicle-free
form (3); or linked to high-density lipoproteins (18). This com-
partmentalization facilitates the purification of specific isolates,
enriching for biomarkers of interest. Moreover, the possibility of
isolating cell lineage-specific exosomes based upon their parental
protein expression patterns, could in principle represent a further
advantage in the identification and validation of biomarkers in
lymphocyte activation.
RELEASE OF EXOSOME-ASSOCIATED miRNAs UPON
ACTIVATION OF LYMPHOCYTES: BIOLOGICAL ASPECTS
The presence of RNA, such as messengers and regulatory RNAs
(among which miRNAs) within exosomes was initially described
in 2007 (19) but the role of exosomes in conveying intercellu-
lar communication had already been extensively investigated in
the immune system [reviewed in Ref. (20, 21)]. In 1996, it was
first demonstrated that B lymphocytes release exosomes with a
significantly different overall surface protein profile from that of
the plasma membrane and that they do contain MHC class II
and are able to induce antigen-specific MHC class II-restricted T
cell responses, demonstrating a specific role for exosomes in anti-
gen presentation in vivo (22). Later it was also shown that upon
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TCR triggering, T lymphocytes produce a large amount of exo-
somes that bear TCR from the pool of activated complexes. It was
suggested that exosomes may work as powerful vehicles to specif-
ically deliver signals to cells with a specific combination of pep-
tide/MHC complexes (23). Furthermore, T lymphocytes have been
observed killing target cells by CD95 engagement through mem-
brane CD95L containing exosomes (24). Exosomes can be viewed
as communication modules between cells of the immune system,
and are regarded by some authors as important to the microenvi-
ronment as the release of cytokines and chemokines (25). While
the role of intracellular miRNAs has long been recognized as a key
level of gene-expression regulation in cells of the immune system
(26, 27), its role in exosomes has only begun to be explored. Ini-
tial data indicate an exosome-mediated transfer of RNA between
T cells and antigen presenting cells during antigen recognition,
as well as the capacity of miRNAs transferred during immune
synapse to modulate gene-expression in recipient cells (28, 29).
To fully elucidate the role of exosome-associated miRNAs, it will
be necessary to better characterize the fundamental processes of
extra-cellular RNA biogenesis, distribution, uptake, and how they
contribute to overall function. In principle, since exosomes contain
myriad miRNAs in varying numbers they possess the potential to
regulate the expression of multiple genes leading to very effective
paracrine control over neighboring cells (30).
LYMPHOCYTE SIGNATURES OF EXOSOME-ASSOCIATED
miRNAs: A NEW LANDSCAPE TO BE UNVEILED
The release of RNA through exosomes is not a passive phenome-
non, but actually a regulated, active process demonstrated by the
fact that exosomal RNA content is not at all a mere reflection
of that found within the intracellular milieu. By next-generation
sequencing of small RNA species present in vesicles released in co-
culture of T lymphocytes and dendritic cells, it has been described
that distinct RNA categories, such as small ribosomal RNA and
specific tRNA fragments, long interspersed elements (LINEs), and
long terminal repeats (LTRs) are conveyed in, and released by
vesicles in significantly greater numbers than other RNA types,
such as lincRNAs (31). A quantitative analysis shows the selective
enrichment of some miRNAs in purified exosomes compared to
cells. The differential rate of release for various RNA molecules
was further demonstrated by our finding that the intracellular
miRNome of CD4+ T lymphocytes is more similar to the intra-
cellular miRNome of B lymphocytes than to their own exosomal
miRNome (Figure 1A) (32). Indeed, we have identified a discrete
set of miRNAs whose intracellular concentrations, compared to
that found within their cognate lymphocyte-derived exosomes,
was significantly different (32).
As previously reported, we have identified 20 intracellular miR-
NAs that are able to distinguish between different subpopulations
of CD4+ T cells, defining the development and differentiation of
this lineage (Figure 1B) (33). Only two of these miRNAs were inde-
pendently demonstrated to be differentially represented in Th cell-
derived compared to B cell-derived exosomes (Figure 1C); further
17 miRNAs with a signature specifically associated to exosomes
released by CD4+ T cells have been subsequently identified (32).
These observations tell us that even a thorough analysis of the bio-
logical relevance of miRNAs at the intracellular level is not helpful
in deciphering the spectrum of differences at the extra-cellular
level and that only a high-throughput quantitative investigation
of miRNA in exosomes will define lymphocyte-specific exosome-
associated miRNA signatures. Consequently, this endeavor com-
menced by showing that CD4+ T and B lymphocytes display sig-
nificantly different selective enrichment of specific extra-cellular
miRNAs, and we are now in the process of fully elucidating the
differential exosomal miRNomes of each CD4+ T subset.
These studies will potentially have two different and equally
relevant impacts on the field. On the one side, the analysis of
extra-cellular lymphocyte signatures may shed light on the role
of miRNA disposal during activation. For example, as previously
described, when primary CD4+ T cells are activated in vitro, they
dramatically down-regulate intracellular miR-150 while accumu-
lating it in extra-cellular vesicles, suggesting that this type of release
may represent an additional layer of post-transcriptional regula-
tion for miRNAs with very rapid effects on target genes of the
discarded miRNAs (32). We thus believe that correlating data
of intracellular modulation upon activation with data of extra-
cellular disposal will tell us if the case of miR-150 is isolated or
not, and if this type of regulation is specific for different lympho-
cyte subsets. Furthermore, should exosome-associated miRNAs
display a paracrine control over neighboring cells, the full descrip-
tion of extra-cellular miRNAs differentially released by different
subsets of effector cells will profoundly change the knowledge we
have on how these cells impact on the extra-cellular environment.
On the other side, these same studies will pave the way for
the identification and validation of potentially powerful biomark-
ers of lymphocyte activation. Indeed, upon the identification of
miRNAs that are differentially released by various lymphocyte
effector cells (e.g., Th1, Th2, Th17, and Treg), the assessment of
their modulation in serum may render possible to mark the elici-
tation of these cells, which occurs in lymphoid tissues or damaged
organs (34).
THE GROWING NEED FOR NEW BIOMARKERS OF
VACCINATION
Vaccinations are based on the activation of the adaptive immune
system. Their efficacy is evaluated mostly by assessing serum anti-
body titers and lymphocyte responses in peripheral blood, despite
T and B cell activation occurring within the lymphoid tissues.
While the protective role of vaccination is primarily conferred by
the generation of B cells-derived antigen-specific antibodies, T
cells are fundamental for the induction of high-affinity antibodies
and immune memory, and in certain types of vaccines, these cells
must be regarded as prime effectors. Then, the identification of
novel immune correlates of vaccine efficacy that take into account
parameters different than antibody titers will become increasingly
more important in the development of new adjuvants and the
optimization of current vaccines (35). Moreover, as some subsets
of effector T helper cells can trigger adverse events from allergy to
autoimmunity, the ability to easily monitor the induction of these
subsets by new vaccines is becoming critical concern in clinical
development.
Toward these ends, a pilot study to address the feasibility of
following the generation of an immune response through the
profiling of serum-associated miRNAs has been undertaken (32).
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FIGURE 1 | MicroRNAs signature of CD4+ T cell-derived exosomes
cannot be predicted by relevant intracellular miRNA signatures of
CD4+ T cells development and differentiation. (A) Pearson correlation
between miRNA expression level in CD4+ lymphocytes and either
miRNA expression level in B lymphocytes (upper panel) or miRNA
representation in CD4+ lymphocyte-derived exosomes (lower panel). R
square values are reported. (B) Schematic view of CD4+ T lymphocytes
with the relative intracellular miRNA signatures identified as relevant for
the development and differentiation of these subsets (EM, effector
memory; CM, central memory). (C) Venn diagram showing the partial
overlap between the 20 miRNAs composing the intracellular signatures
of CD4+ T subsets of panel B and the 19 miRNAs at later stage
identified for being either exclusive or differentially up-represented in
exosomes derived from CD4+ T subsets compared to exosomes
derived from B lymphocytes. Data shown are adapted from previous
published studies (32, 33).
EXOSOME-ASSOCIATED miR-150 AS A GENERAL SENSOR
OF VACCINATION
Over the past few years, one specific miRNA, namely miR-150,
has been confirmed to play a critical role in the development
of lymphoid and myeloid lineages in both mice and humans
(36). In particular, miR-150 is expressed at a low level in B- and
T-progenitor cells, but gets highly up-regulated in mature lym-
phocytes. Moreover, as naïve T cells differentiate into effector Th
cells, the level of miR-150 is down-modulated again (37).
miR-150 has been also frequently observed to be dramatically
dysregulated in several types of leukemias and lymphomas (36).
When the level of intracellular miR-150 decreases, some critical
targets get de-repressed, e.g., c-Myb, a transcription factor that
promotes lymphocyte survival by inducing Bcl2 (38, 39). Another
target of miR-150 action is Notch3, a member of the Notch family
of receptors, which plays a pivotal role in T cell differentiation and
leukemogenesis (40).
We recently described that when primary human CD4+ Th
cells dramatically down-regulate intracellular miR-150 upon acti-
vation, it’s released by exosomes, suggesting that this process of
extra-cellular miRNA “disposal” may represent an additional layer
of post-transcriptional down-regulation for miRNAs with very
rapid effects on target genes that critically control lymphocyte
responses (32).
In parallel with the biological implications of these observa-
tions, we decided to investigate miRNA-150 as a potential candi-
date for the optimal biomarker of lymphocyte activation because:
(i) it is highly expressed in both human lymphocyte cells and
lymphocyte-derived exosomes; (ii) it is expressed specifically in
spleen compared to other human tissues, supporting the idea that
the major source of serum miR-150 are lymphoid cells and (iii) it is
easily detectable and significantly enriched in exosomes circulating
in human blood (32). Hence, our working hypothesis is based on
the assumption that when the immune system is activated by vacci-
nation, the lymphocytes that participate in the response will release
an easily detectable number of exosomes into the bloodstream and
consequently a readily measureable level of a lymphocyte-derived
exosomal miRNA (as it is the case for miR-150) (Figure 2A). Before
proceeding to analyze precious human samples of vaccinated indi-
viduals, we made use of the mouse model, and discovered that, as
correctly hypothesized, serum miR-150 levels increase significantly
in mice upon vaccination with adjuvant-OVA. Instead, miR-150
serum concentrations remain unchanged in immunized mice that
are depleted of mature CD4+ T lymphocytes [major histocompat-
ibility complex class II-deficient mice (41)] showing that serum
miR-150 modulation is a specific phenomenon strictly dependent
on adaptive immune responses elicited by effective vaccination
(Figure 2B) (32).
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FIGURE 2 | Serum circulating miR-150 increases in both human and mice
upon vaccination. (A) Schematic view of exosome-associated miR-150
release upon induction of adaptive immune response in secondary lymphoid
organs upon vaccination. (B) Mouse serum circulating miR-150 increase
expressed as relative quantities at time T0 (pre-vaccination) and T1
(post-vaccination) in wild type compared to CD4+ cell-depleted MHCII knock
out mice (four animals/group; the result shown is representative of two
independent experiments). (C) Human circulating miR-150 increase
expressed as fold change upon vaccination in total serum compared to serum
purified exosomes (results come from 17 paired samples of sera collected at
the time of vaccination and 4 weeks after that). Data shown are adapted from
previous published studies (32).
Sera from adults or children vaccinated with the 2009 pandemic
flu (H1N1) vaccine adjuvanted with MF-59 (42) was then assessed
and, similarly to what was found in mice, the level of extra-cellular
miR-150 increased significantly in human serum upon vaccination
and this increase was significantly more evident upon purifica-
tion of exosomes (Figure 2C) (32). This observation suggests
that serum miR-150 modulation is specifically compartmental-
ized to lymphocyte-derived vesicles and that exosome purification
strategies from blood may serve to increase lymphocyte biomarker
sensitivity by enriching immune-related circulating extra-cellular
RNAs, as suggested for other conditions (7, 43). Furthermore, in
flu vaccinated individuals, miR-150 serum levels post-vaccination
have been found to be significantly higher in people mount-
ing higher antibody response, showing a quantitative correlation
between the modulation of a circulating miRNA and the adaptive
immune response (32).
In a recent study, reduced miR-150 serum concentrations have
also been found to be associated with an unfavorable outcome
in critically ill patients with sepsis. It has been hypothesized that
lower circulating miR-150 levels might lead to de-repression of
genes such as CXCR4 and c-Myb, both linked to immune response
activation and poor prognosis (14).
Consistently, we do speculate that the significant uptick in cir-
culating miR-150 levels that coincides with vaccination may play a
role in down-modulating adaptive immune responses by carrying
extra-cellular messages to other immune cells and consequently
regulating miR-150 target genes.
Obviously, as miR-150 is ubiquitous across all lymphocyte
populations, it may only serve as a generic lymphocyte activa-
tion sensor, devoid of more insights into the lymphocyte subsets
involved. Nonetheless, this study has provided the first proof-
of-concept that serum miRNAs can be readily detected, from a
minimally invasive serum sample, toward their validation as sen-
sitive and specific biomarkers of vaccination, and more generally
of the adaptive immune response.
SUMMARY AND PERSPECTIVES
Blood-circulating extra-cellular miRNAs have the potential to
become highly valuable biomarkers in the near future. In particu-
lar, the identification of serum miRNA signatures able to directly
report the differential activation state of clinically relevant lym-
phocytic subsets may become an innovative tool to provide pivotal
information about the nature of the immune responses occur-
ring in health (e.g., vaccination) and disease (e.g., auto-immune
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and immune-mediated disorders). We have recently described a
significant increase of circulating miR-150 serum concentrations
1 month post-vaccination,and shown to be the release of exosome-
associated miRNAs by lymphocytes activated in vivo by vaccines.
This study gives support to the idea that profiling of serum miRNA
levels may lead to the identification of new biomarkers of immune
responses and that exosome purification represents a facile yet
powerful step toward increased sensitivity, with possible increased
specificity.
In conclusion, the compilation of a catalog of exosome-
associated miRNAs derived from specific lymphocyte subsets
should help confirm whether serum miRNAs are indeed able to
report the activation of specific T cell subsets (e.g., Th1, Th2,
Th17, Treg, etc.) occurring at distant sites. These lines of enquiry
should benefit the assessment of pathogenic immune response
during the course of auto-immune diseases and their therapies,
as well as significantly contributing to the close, rapid monitoring
of clinical trials with new immune-regulatory drugs, new vac-
cines, and/or adjuvants, particularly in the earlier stages of clinical
development.
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